Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CT-95
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Context Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Details : Context Therapeutics acquires CT-95, a potential first-in-class mesothelin x CD3 bispecific antibody, which is ready Phase 1-ready T cell Engager for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : CT-95
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Context Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
